NAD+ (nicotinamide adenine dinucleotide) sits at the center of some of the most compelling longevity and cellular health research of the past decade. Its role in energy metabolism has been known for over a century — but its connections to aging biology, DNA repair, and sirtuin activation have made it one of the most actively researched molecules in longevity science.
Here’s a complete breakdown of the research for scientists and researchers following this field.
What Is NAD+?
NAD+ is a coenzyme found in every living cell. It exists in two forms:
- NAD+ — the oxidized form (accepts electrons)
- NADH — the reduced form (donates electrons)
The cycling between these two forms is fundamental to cellular energy metabolism. NAD+ serves as an electron carrier in oxidative phosphorylation — the process by which mitochondria generate ATP from glucose and fatty acids.
But NAD+’s role extends far beyond energy metabolism. It is also a substrate for several classes of enzymes with critical functions in cellular maintenance and longevity biology.
Why NAD+ Declines With Age
One of the most significant research findings of the past 20 years: NAD+ levels decline substantially with age — by roughly 50% between young adulthood and middle age in most tissues studied, with continued decline thereafter.
Several mechanisms contribute to this decline:
Increased NAD+ Consumption
- PARP activation: PARPs (poly ADP-ribose polymerases) are DNA repair enzymes that consume NAD+ as a substrate. As DNA damage accumulates with age, PARP activity increases — consuming more NAD+.
- CD38 upregulation: CD38 is an NADase enzyme that cleaves NAD+. CD38 expression increases with age and with chronic inflammation — a phenomenon sometimes called “inflammaging.” CD38 may be responsible for a significant portion of age-related NAD+ decline.
- SARM1 activity: SARM1 is an NAD-cleaving enzyme expressed in neurons, relevant to neurodegeneration research.
Decreased NAD+ Biosynthesis
- Declining expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway — the primary NAD+ biosynthesis route in most tissues
- Reduced efficiency of NAD+ precursor conversion in aged cells
NAD+-Dependent Enzymes: The Research Connection to Aging
NAD+’s connection to aging biology comes primarily through enzymes that require it as a substrate:
Sirtuins (SIRT1–7)
Sirtuins are NAD+-dependent deacylases that regulate numerous cellular processes:
- SIRT1: Gene expression regulation, mitochondrial biogenesis (via PGC-1α), metabolic homeostasis, stress response
- SIRT3: Mitochondrial protein deacetylation, oxidative stress regulation
- SIRT6: DNA repair, telomere maintenance, inflammation regulation
- SIRT7: Ribosomal DNA transcription, chromatin organization
Sirtuin activity is directly dependent on NAD+ availability — lower NAD+ means reduced sirtuin activity. Since sirtuins regulate dozens of longevity-relevant pathways, NAD+ decline has cascading effects across cellular maintenance systems.
PARPs (DNA Repair)
PARPs are critical for DNA strand break repair. PARP1 alone accounts for up to 90% of total cellular PARP activity and is responsible for significant NAD+ consumption during periods of DNA damage. The competition between DNA repair demands (PARPs) and metabolic/longevity signaling (sirtuins) for NAD+ is a central tension in aging biology research.
CD38 (Immune Regulation)
CD38 plays roles in immune cell activation and calcium signaling. Its upregulation with age and inflammation creates a positive feedback loop: inflammation increases CD38 → CD38 depletes NAD+ → lower NAD+ impairs cellular maintenance → accelerated aging phenotypes.
NAD+ and Mitochondrial Function
Mitochondrial dysfunction is one of the hallmarks of aging (Lopez-Otin et al., 2013). NAD+ is central to mitochondrial energy production:
- NAD+ is required for the TCA cycle (Krebs cycle) — multiple steps produce NADH that feeds the electron transport chain
- SIRT3 (a mitochondrial sirtuin) requires NAD+ to deacetylate and activate key metabolic enzymes
- NAD+ supplementation in aged animal models has been associated with improved mitochondrial biogenesis and function markers
Research in aged rodents has shown that NAD+ precursor supplementation (NMN, NR) can partially restore mitochondrial function metrics — muscle endurance, energy metabolism, and mitochondrial morphology — toward values seen in younger animals.
Key Clinical and Preclinical Research
NMN and NR as NAD+ Precursors
Direct NAD+ supplementation is poorly bioavailable — the molecule is too large to efficiently cross cell membranes. Research has therefore focused on precursors that cells convert to NAD+:
- NMN (nicotinamide mononucleotide) — enters cells via the Slc12a8 transporter (recently discovered); also converts to NR extracellularly
- NR (nicotinamide riboside) — well-characterized oral bioavailability in human studies
- Niacin (NA) and Nicotinamide (NAM) — older precursors; niacin effectively raises NAD+ but with significant flushing side effects at therapeutic doses; NAM raises NAD+ but may inhibit sirtuins at high concentrations
Human Studies (NR)
- Trammell et al. (2016): Oral NR safely and effectively raised blood NAD+ in healthy adults — first robust human pharmacokinetic data
- Martens et al. (2018): 6-week NR supplementation in older adults raised NAD+ metabolome; reduced aortic stiffness in a subgroup with elevated baseline levels
- Dollerup et al. (2018): NR supplementation in obese men raised NAD+ but did not significantly change insulin sensitivity or other metabolic markers at 12 weeks
Human Studies (NMN)
- Yoshino et al. (2021): NMN supplementation in postmenopausal women with prediabetes improved muscle insulin sensitivity and signaling — first significant human metabolic outcome data for NMN
- Multiple smaller studies have confirmed NMN raises blood NAD+ levels in humans
Notable Animal Studies
- Mills et al. (2016): Long-term NMN administration in aged mice improved energy metabolism, physical activity, body weight, eye function, and bone density
- Gomes et al. (2013): NAD+ decline shown to cause pseudohypoxic response in aged muscle; NMN treatment reversed this — landmark mechanistic paper
- Zhang et al. (2016): NAD+ shown to protect against noise-induced and age-related hearing loss in mice via SIRT3
NAD+ and DNA Repair: The PARP-Sirtuin Competition
One of the most interesting findings in NAD+ aging research is the competitive relationship between DNA repair and longevity signaling:
- DNA damage accumulates with age
- PARPs are activated to repair damage — consuming large amounts of NAD+
- Lower NAD+ availability reduces sirtuin activity
- Reduced SIRT1/SIRT6 activity impairs the cell’s ability to maintain epigenetic marks and regulate stress responses
- This creates a declining spiral: more damage → more PARP activity → less NAD+ → less protective signaling → more damage
David Sinclair’s lab (Harvard) has published extensively on this cascade, proposing it as a central mechanism of aging. NAD+ supplementation is theorized to restore sirtuin activity even in the context of ongoing DNA repair demands.
NAD+ Research: Current Frontiers
Neurodegeneration
NAD+ metabolism is increasingly studied in Alzheimer’s, Parkinson’s, and ALS research. SARM1 (an NAD+-cleaving enzyme) drives axonal degeneration in neuronal injury models — SARM1 inhibition is an active therapeutic target. NR supplementation has shown neuroprotective effects in some animal models.
Cardiovascular Research
NAD+ precursor supplementation has been associated with improved endothelial function and reduced arterial stiffness in some human studies. SIRT1 and SIRT3 regulate mitochondrial function in cardiomyocytes — pathways relevant to heart failure research.
Cancer Biology
NAD+ metabolism in cancer cells is an active research area — cancer cells often upregulate NAMPT to support their elevated NAD+ demands. This has made NAMPT an explored therapeutic target, though the interaction between NAD+ supplementation and cancer biology requires careful research attention.
Metabolic Disease
NAD+-related pathways (sirtuins, AMPK signaling) are closely connected to insulin sensitivity, fat metabolism, and metabolic homeostasis — areas with significant ongoing research interest.
Research Forms Available
BLL Peptides carries NAD+ for research applications — pharmaceutical grade, third-party COA verified. →
NAD+ Research Compounds
Pharmaceutical grade. Third-party COA on every batch. → bllpeptides.com
Related Research
Disclaimer: This content is for research and educational purposes only. BLL Peptides products are intended for laboratory research use only and are not intended for human or veterinary use. This does not constitute medical advice. Consult a licensed healthcare professional before making any health decisions.